Autolus Therapeutics plc EBITDA 2011-2026 | AUTL

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Autolus Therapeutics plc

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-234 M	-173 M	-136 M	-133 M	-162 M	-141 M	-23.3 M	-22.4 M	-13.9 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-13.9 M	-234 M	-115 M

Quarterly EBITDA Autolus Therapeutics plc

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-69.5 M	-59.1 M	-63.2 M	-66 M	-57 M	-37 M	-41.5 M	-42.9 M	-37.2 M	-	-41.7 M	-	-	-	-	-	-38.2 M	-	-41.2 M	-38.3 M	-37.3 M	-	-34.5 M	-36.1 M	-28.5 M	-24.4 M	300 K	500 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
500 K	-69.5 M	-39.6 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	1.19 M	$ 0.79	-1.15 %	$ 4.31 M	China
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
AbCellera Biologics ABCL	-199 M	$ 3.49	0.58 %	$ 1.04 B	Canada
Frequency Therapeutics FREQ	-118 M	-	-	$ 528 M	USA
argenx SE ARGX	-349 M	$ 700.45	-1.19 %	$ 25 B	Niderland
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.6	1.41 %	$ 8.66 B	Australia
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Grifols, S.A. GRFS	595 M	$ 7.81	-2.01 %	$ 6.83 B	Spain
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Ascendis Pharma A/S ASND	-452 M	$ 225.98	-1.32 %	$ 5 B	Danmark
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
ADC Therapeutics SA ADCT	-262 M	$ 4.13	-5.06 %	$ 105 M	Schweiz
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	-65 M	-	10.36 %	$ 9.8 M	USA
BioCardia BCDA	-11.6 M	$ 1.26	-0.79 %	$ 26.7 M	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Anika Therapeutics ANIK	-81.2 M	$ 14.2	-0.7 %	$ 208 M	USA
Aptose Biosciences APTO	32 K	-	-45.71 %	$ 1.2 M	Canada
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Athersys ATHX	-85.6 M	-	3.77 %	$ 22.4 M	USA
BioNTech SE BNTX	15.3 B	$ 91.19	1.21 %	$ 27.2 B	Germany
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Arcturus Therapeutics Holdings ARCT	-73.2 M	$ 6.68	-4.57 %	$ 183 M	Israel
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
AVEO Pharmaceuticals AVEO	-49.5 M	-	-	$ 521 M	USA
Burford Capital Limited BUR	242 M	$ 7.92	1.67 %	$ 1.31 B	Britain
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-2.45 M	$ 2.54	-5.22 %	$ 16 M	USA
Certara CERT	96.2 M	$ 6.67	1.6 %	$ 1.07 B	USA
Athira Pharma ATHA	-99.9 M	-	-	$ 269 M	USA
Can-Fite BioPharma Ltd. CANF	-10.1 M	$ 3.6	-4.0 %	$ 7.83 B	Israel
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Brainstorm Cell Therapeutics BCLI	-11.5 M	-	-2.5 %	$ 5.88 M	USA